Fusemachines given 180 days to cure Nasdaq bid price deficiency

Micro-cap equities trading below the one-dollar threshold face a standardized regulatory clock, a mechanism that enforces listing standards without immediate delisting. Fusemachines Inc. (Nasdaq: FUSE) received a notification letter from The Nasdaq Stock Market on September 18, 2026, confirming its common stock has traded below the minimum bid price requirement for 30 consecutive business days. The company remains listed on the Nasdaq Global Market, but it now has until March 17, 2027, to regain compliance with Nasdaq Listing Rule 5450(a)(1).

The Compliance Window

The notification has no immediate effect on the trading of Fusemachines securities. Under Nasdaq Listing Rule 5810(c)(3)(A), the company is afforded a 180-calendar-day period to cure the deficiency. To resolve the matter, the closing bid price of the common stock must reach or exceed $1.00 per share for a minimum of 10 consecutive business days. Nasdaq retains discretion to extend this observation period to up to 20 consecutive business days. If the company fails to meet this standard by the deadline, it may transfer its listing to The Nasdaq Capital Market. Such a transfer would grant an additional 180-day compliance period, provided the firm meets all other initial listing standards for that tier, including market value of publicly held shares, and formally notifies Nasdaq of its intent to cure the deficiency.

Macro Read-Through

The broader cycle for small-cap issuers is increasingly defined by liquidity constraints and the cost of maintaining exchange status. For a firm with a par value of $0.0001 per share, the discount rate applied to its equity value is sensitive to the bid price, which serves as the primary metric for continued listing eligibility. The company’s status as an emerging growth company, a designation that allows for extended transition periods on certain financial accounting standards, does not exempt it from the minimum bid price rule. The read-through for investors is that the capex cycle and operational performance must translate into sustained market capitalization growth to avoid a tier downgrade.

Path Forward

Fusemachines intends to actively monitor the bid price and evaluate available options to regain compliance within the specified period. The company’s chief executive officer, Sameer Maskey, signed the Form 8-K filing, which includes forward-looking statements regarding its ability to improve or sustain its market value. These projections are subject to risks beyond the company’s control, including market conditions and financial performance. The filing references the company’s Annual Report on Form 10-K filed in March 2026 and its Registration Statement on Form S-4 declared effective in June 2025. On balance, the immediate risk is not delisting but the potential administrative burden and investor perception associated with a transfer to the Nasdaq Capital Market if the bid price remains suppressed through March 2027.